Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers

Executive Summary

FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.

Advertisement

Related Content

Roche Builds Hematology Pipeline Beyond B-Cell Disease
Roche Hits Goal For Gazyva Expansion With Follicular Lymphoma Approval
A “Breakthrough” Reality Check: Sponsors Seek FDA Flexibility On Manufacturing, Diagnostics
CDER Approvals In January Came Early And Often

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel